Stephen MacMahon

The George Institute for Global Health provides research and development for international health. It develops tools to empower people to improve their own health. The firm also uses mobile technology to make healthcare accessible worldwide and improves outcomes among stroke survivors. It helps preventing complications of diabetes. The company was founded by Stephen MacMahon and Robyn Norton in 1999 and is headquartered in Sydney, Australia.

UK Biobank Ltd. is a biomedical database and research resource that contains genetic, lifestyle, and health information from half a million participants aged between 40-69 years in 2006-2010 from across the UK. The organization has over 220 dedicated members of staff, based in multiple locations across the UK. UK Biobank's research resource is a major contributor to the advancement of modern medicine and treatment, enabling better understanding of the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, and stroke. The non-profit company is based in Stockport, UK, and has subsidiaries in the United Kingdom. The database includes blood samples, heart and brain scans, and genetic data that are accessible to approved researchers who are undertaking health-related research that is in the public interest. The CEO of the British company is Rory Collins.

George Clinical Pty Ltd. provides clinical research services. It offers robust operational expertise and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology. The company was founded by Stephen MacMahon in 2008 and is headquartered in Newtown, Australia.

The Oxford Health Alliance is a British charitable company that focuses on preventing chronic diseases. The non-profit company is based in Greater London, UK.

George Medicines UK Ltd. is a company focused on late stage drug development to improve the management of non-communicable diseases. The company is based in London, UK. The British company does this by creating single-pill, multi-mechanism combinations of existing medicines. Stefan König has been the CEO of the company since 2021.